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A b s t r A c t
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem 
cell disorder, caused by a somatic mutation in the phosphatidylinositol glycan (PIG-A) 
gene class A. The gene is responsible for the synthesis of glycophosphatidylinositol 
(GPI) anchor that attaches a number of proteins to the cell surface. The mutant gene 
leads to partial deficiency or absence of all proteins normally linked to the cell mem-
brane by GPI anchor. The primary clinical manifestations of PNH are complement 
mediated hemolytic anemia, thrombosis in atypical locations and blood cytopenias. 
Flow cytometry has become the gold standard method for PNH clone detection due 
to its high sensitivity and specificity and due to the ability to examine multiple GPI-
linked proteins on red and white blood cell surface. It is the method of choice for 
the detection of very small PNH clones in subclinical PNH that often accompanies 
aplastic anemia and other bone marrow disorders. PNH clone detection traditionally 
involves the analysis of CD55 and CD59 on red and white blood cells. Other markers 
such as CD14, CD16, CD24, CD66b and CD157 are suitable to detect GPI-linked pro-
teins in the surface of granulocytes and monocytes. The most useful reagent to assess 
white blood cell PNH clones is fluorescent aerolysin (FLAER), which is a mutated 
form of proaerolysin conjugated with a fluorochrome. Its advantage in PNH clone 
detection is due to the ability to bind directly to the glycan portion of the GPI anchor. 
Flow cytometry is a sophisticated method and a useful tool for clinical cell analysis. 
However, PNH is clinically diagnosed and flow cytometric results should always be 
interpreted with respect to clinical manifestations and other laboratory findings.
I n t r o d u c t I o n
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, clonal disorder 
occurring in a hematopoietic stem cell. It is caused by a mutation of the X-linked 
phosphatidyl-inositol glycan, (PIG-A) gene class A. PIG-A gene is responsible for 
the first step in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor, a 
glycolipid structure that attaches more than 12 different proteins to the cell surface 
of blood cells, including blood group antigens, adhesion molecules and complement 
regulatory molecules.1 PIG-A gene is located on the X chromosome, however, PNH 
affects males and females almost equally. That is because males have only one X chro-
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mosome and females undergo lyonization (inactivation of one 
X chromosome) in somatic cells, including hematopoietic stem 
cells.1 A large spectrum of acquired PIG-A mutations have 
been described, the majority of which results in an unstable 
and rapidly degraded protein. In most cases, mutations are 
unique to a patient, suggesting the absence of a mutational 
hot spot in the gene.1 The genetic defect results in partial or 
absolute deficiency of all GPI-linked proteins in a clone of 
hematopoietic stem cells and consequently in all lineages aris-
ing from it. Deficient cells are referred to as “PNH clones”.
PNH manifests with three distinctive clinical features. 
Complement mediated hemolytic anemia is the best described 
and most clinically significant consequence of GPI-linked 
protein reduction.2 In normal individuals, two GPI-linked 
proteins protect red blood cells (RBCs) from complement ac-
tivity. Decay accelerating factor or CD55 is one of them. CD55 
protects RBCs from hemolysis by inhibiting C3 convertases 
which enzymatically cleave and activate C3. In the absence of 
CD55, C3 accumulates on the surface of RBCs and causes their 
destruction by the reticuloendothelial system in the liver and 
spleen (extravascular hemolysis).3 Membrane inhibitor of reac-
tive lysis  or CD59 is another GPI-linked protein that prevents 
RBCs from the lytic activity of the complement by blocking 
the aggregation of C9 into the membrane attack complex. 
Membrane attack complex is the final stage of complement 
activation which forms pore in the target cell. The absence of 
CD59 from the RBC surface leads to intravascular hemolysis 
which most contributes to the morbidity of the disease.4 Many 
of the symptoms that accompany PNH, such as dysphagia, 
recurrent abdominal pain, erectile dysfunction, fatigue, and 
severe lethargy, are due to reduced level of nitric oxide.5 Nitric 
oxide is produced in the endothelium and regulates vascular 
and smooth muscle tones and limits platelet activation. Free 
hemoglobin released from RBCs during intravascular hemoly-
sis scavenges circulating nitric oxide, consumption of which 
causes vasoconstriction and smooth muscle dystonia.
Thrombosis is another complication of PNH and the most 
common cause of mortality.6 The pathogenesis of thrombosis 
involves a multifactorial mechanism in which platelet activa-
tion, free hemoglobin, nitric oxide depletion, impairment of 
the fibrinolytic system and inflammatory mediators take part. 
Thrombotic events may occur at any site, although venous 
thrombosis is more common than arterial. They often arise 
in atypical locations particularly in cerebral, hepatic (Budd-
Chiari syndrome), portal, mesenteric, splenic, renal and 
pulmonary veins.
Bone marrow failure is the third element that accompanies 
PNH. It occurs in almost all patients but its severity varies. 
Aplastic anemia (AA) is the most extreme form.7
The International PNH Interest Group proposed a clas-
sification scheme for PNH consisting of three main categories: 
1) classical PnH includes patients with clinical evidence 
of intravascular hemolysis or hemolysis but no evidence of 
another defined bone marrow abnormality; 2) PnH in the 
setting of another specified bone marrow disorder; patients 
in this category have clinical and laboratory evidence of PNH 
and a defined underling bone marrow abnormality, such as 
acquired AA or myelodysplastic syndrome (MDS) of refractory 
cytopenias with unilineage dysplasia (RCUD) type (according 
to the last WHO classification); 3) subclinical PnH includes 
patients with another bone marrow disorder (AA, MDS) who 
have no clinical or laboratory evidence of hemolysis or throm-
bosis. However in these patients, small PNH clones can be 
detected in peripheral blood by very sensitive flow cytometric 
analysis.8 The close relation of acquired AA and PNH is well 
documented in the literature, but the exact pathophysiologic 
mechanism that links the two disorders remains unclear. AA 
and PNH are bone marrow disorders in which hematopoietic 
stem cell damage stands as common denominator; in case of 
AA by an autoimmune attack and in PNH by a PIG-A gene 
mutation.9 AA may precede PNH diagnosis or less frequently 
may arise in the setting of preexisting PNH. More than 50% 
of AA patients demonstrate PNH clones at diagnosis.10,11 The 
clinical significance and the prognostic value of these clones re-
main controversial. These clones are often very small and they 
may increase or decrease over time. There are cases in which 
PNH emerges after immunosuppressive therapy for AA.10,12
Rarely do patients with MDS reveal classic PNH. The fact 
is explained by the different cells in which PIG-A mutation oc-
curs. In acquired AA, PIG-A mutation occurs in hematopoietic 
stem cell that can self-renew and give rise to all hematopoietic 
cell lineages. In MDS the mutation arises in colony forming 
cells which lack self-renewing ability and are able to survive 
only for three to four months.13
I n d I c A t I o n s  f o r  P n H  t e s t I n g
PNH is a rare disorder that can present with a wide range of 
clinical signs and symptoms of which none is pathognomonic. 
However, some clinical presentations raise suspicion for PNH 
and need further investigation. Patients presenting with he-
moglobinuria should be tested for PNH, as well as patients 
with Coombs-negative hemolytic anemia, particularly those 
without characteristic cellular abnormalities, such as sickled 
cells or schistocytes and no obvious infection that can cause 
hemolysis. Although thrombosis is a common complication, 
routine screening of all patients with a thromboembolic event 
is not recommended unless thrombosis appears in unusual 
sites. Budd-Chiari syndrome, thrombosis of intra-abdominal 
vessels (inferior vena cava, portal or splenic vein), dermal 
and cerebral veins are indications for PNH testing, especially 
if cytopenias and/or intravascular hemolysis coexist. Patients 
with evidence of bone marrow failure including aplastic or 
hypoplastic anemia, RCUD and unexplained cytopenia should 
be investigated for the presence of PNH clones.8,14 A summary 
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of the indications for PNH testing is presented in Table 1.
I m m u noPH e no t y PI ng A nA lysI s of Pn H c e l l s
Prior to the last two decades, acidified serum lysis test 
(Ham test) and sucrose lysis test were the classic diagnostic 
methods to demonstrate the sensitivity of RBCs to complement 
activation.15 However, both tests were nonspecific and unable 
to quantitate the percentage of PNH clones. In 1990, van der 
Schoot and coworkers demonstrated that the use of mono-
clonal antibodies to GPI-linked proteins and flow cytometry 
were suitable in the analysis of granulocyte PNH clones.16 A 
year later, Rosse et al and Shichishima et al published their 
work about the detection of GPI-linked proteins on the sur-
face of RBCs in PNH by flow cytometry.17,18 Flow cytometry 
has become the gold standard method in the diagnosis and 
monitoring of PNH due to its high sensitivity and specificity 
and the ability to examine multiple GPI-linked proteins in the 
surface of multiple blood cell lineages.14
The preferred specimen for PNH testing by flow cytometry 
is peripheral blood collected in ethylenediaminetetraacetic 
acid, heparin or acid citrate dextrose solution. Testing is recom-
mended to be performed preferably within 24-48 h of collec-
tion. Bone marrow samples should not be used routinely but 
only in the setting of a research protocol. This limitation is due 
to the presence of immature cells of both erythroid and myeloid 
lineage in which GPI-linked proteins are underexpressed.14 
Flow cytometry is performed by incubating peripheral blood 
cells with fluorochrome labeled monoclonal antibodies that 
bind to GPI-linked proteins. Deficiency or absence of GPI-
linked proteins from the cell surface indicates the presence 
of PNH clones. PNH is a clinical diagnosis that has to be 
confirmed by flow cytometric examination of peripheral blood 
in which reduction of at least two GPI-linked proteins on ³two 
or more cell lineages has to be established1,19.
r e d  b l o o d  c e l l  A n A l y s I s
In high sensitivity flow cytometric assays, recognition of 
mature RBCs relies on CD235a (glycophorin A), a monoclonal 
antibody that is used for RBCs acquisition and analysis to fur-
ther parameters. High sensitivity assays are mandatory for the 
detection of small PNH clones in patients with AA or RCUD.14 
Regarding RBC evaluation for PNH clones, the first and most 
frequently studied GPI-linked antigens are CD55 and CD59. 
However, CD55 is inferior to CD59, as it is less abundantly 
expressed on RBCs and does not offer the best separation 
of RBC types.14,20 For this reason it is not recommended to 
be used as a sole reagent. Three different RBC types can be 
identified and quantified regarding the expression of those 
two GPI-linked proteins. Type I RBCs are characterized by 
normal GPI-linked protein expression, type II RBCs show 
partial deficiency and type III complete absence of GPI-linked 
proteins.14 The distribution of these RBC populations show 
a wide range among patients and the distinction between the 
various types is not always clear (Fig. 1). Type III RBCs are 
the most sensitive to complement-mediated lysis in vivo. It is 
important to mention that RBC testing alone is not sufficient 
for PNH clone evaluation because hemolysis and/or hemodi-
lution due to transfusion may underestimate the clone size14. 
For these reasons, PNH testing should always be provided 
on both white leukocytes and RBCs. PNH clones on white 
blood cells (WBCs) may be detected in the absence of RBC 
ones, but significant RBC clones are never seen without WBC 
clones.20 The most common ways of depicting flow cytometric 
results are histograms, dot and density plots. Single color 
histogram displays the intensity of the signal recorded on the 
x axis with the number of cells displaying intensity on the y 
axis. It is suitable for separation and quantification of type II 
and type III cells when they represent enough events to form a 
separate peak.14 When PNH clones represent a small number 
of events, dot or density plot are more appropriate to ensure 
that they represent a distinct population.14,20 High sensitivity 
flow cytometric analysis is capable of detecting small PNH 
clones represented by 20 clustered type III events in a total 
of one million RBCs.20
w H I t e  b l o o d  c e l l  A n A l y s I s
Granulocytes and monocytes are the optimal cell type 
for evaluation of the PNH clone size, especially in heavily 
pretransfused patients.14,20 That is because the life span of 
tAble 1. Indications for PNH testing
• Patients with hemoglobinuria
• Patients with Coombs negative hemolytic anemia, especially 
patients without cellular characteristic abnormalities or 
infection
• Patients with venous thrombosis involving unusual sites
- Budd – Chiari syndrome
- Other intra - abdominal veins (e.g. portal, mesenteric, 
splenic)
- Cerebral veins
- Dermal veins
• Patients with bone marrow failure syndromes (e.g. aplastic or 
hypoplastic anemia, RCUD)
- Aplastic or hypoplastic anemia
- Refractory cytopenias with unilineage dysplasia
- Other cytopenias of unknown origin
PNH = paroxysmal nocturnal hemoglobinuria; RCUD = refractory 
cytopenias with unilineage dysplasia
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PNH granulocytes is normal and the proportion of GPI-linked 
deficient granulocytes reflects the PNH clone size more ac-
curately.8 In contrast, lymphocytes are not suitable for PNH 
testing because of their prolonged life span and the variability 
of GPI-linked proteins expressed in their surface. Lymphocytes 
arising after the onset of the disorder will be deficient in GPI-
linked proteins as granulocytes and monocytes. However, these 
lymphocytes represent a minority of the entire population. 
The majority of lymphocytes which are “older”, as they had 
arisen before gene mutation, will express GPI-linked proteins 
fIgure 1. High sensitivity flow cytometric evaluation of RBC PNH clones. CD59 expression on RBCs in three cases with different 
percentages of PNH clones shown on dot plots (left column) and on histograms (right column). The three different PNH types are 
shown in black (type I), grey (type II) and light grey (type III). The RBCs are gated by CD235a (not shown). PNH = paroxysmal 
nocturnal hemoglobinuria; RBCs = red blood cells.
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fIgure 2. High sensitivity flow cytometric evaluation of WBC PNH clones. Granulocytes (green) and monocytes (pink) are identi-
fied on the basis of CD45 vs side scatter (top left) and CD33 vs CD15 dot plot (top right). Each of these populations is displayed on a 
CD33 vs FLAER dot plot (bottom row). PNH granulocytes (orange) are shown in the bottom left plot and PNH monocytes (purple) 
in the bottom right plot. FLAER = fluorescent aerolysin; PNH = paroxysmal nocturnal hemoglobinuria; WBCs = white blood cells.
normally.14,21
In high sensitivity flow cytometric analysis of granulocytes 
and monocytes, meticulous gating is assured by using lineage 
specific non-GPI-linked markers, such as CD15 for granulo-
cytes and CD33 or CD64 for monocytes, combined with light 
scatter and/or CD45 expression (Fig. 2).14 Traditionally, CD55 
and CD59 are used to detect PNH clones in WBCs as well as 
in RBCs but these markers are not sensitive enough to assure 
the detection of small (<1%) PNH clones in WBCs, especially 
when the investigation concerns AA and RCUD cases. Other 
markers such as CD14, CD16, CD24, CD66b and CD157 
are suitable to detect GPI-linked proteins in the surface of 
granulocytes and monocytes.14,22 However, there are still some 
limitations, as low expression of a marker does not always mean 
deficiency or absence of a GPI-linked protein; CD16 may be 
absent from granulocytes in case of myelodysplasia and CD14 
is not expressed in immature monocytes.14 The most useful 
reagent to assess the WBC PNH clones is fluorescent aerolysin 
(FLAER).23 FLAER represents a mutated form of proaeroly-
sin secreted by Aeromonas hydrophila. It is conjugated with 
a fluorochrome and the advantage in PNH clone detection is 
due to the ability to bind directly to the glycan portion of the 
GPI anchor. The proportions of PNH clones in granulocytes 
and monocytes are almost equal.14 FLAER cannot be used to 
assess PNH clones in RBCs.14,20-23 The lower limit of sensitivity 
in WBC PNH clone detection has not been determined. How-
ever, the combination of more than one GPI-linked marker 
with FLAER in multiparameter flow cytometry and rare event 
analysis enhances the sensitivity to 0.01%.14
r e P o r t I n g  r e s u l t s  A n d 
I n t e r P r e t A t I o n
In the flow cytometry report of PNH evaluation, clinicians 
get information concerning proportions of PNH clones in 
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RBCs and WBCs (granulocytes and monocytes). As detailed 
above, PNH RBC clones are identified by the reduced level of 
GPI-linked proteins CD55 and CD59. The percentage of each 
of the three RBC types (I, II and III) has to be recorded in the 
flow cytometric report.14 The percentage of RBC clones is very 
often lower than the corresponding WBC clones. As already 
mentioned, this is due to the shorter life span of RBC clones 
or to hemodilution caused by transfusion. There is no clear 
cut off value of RBC PNH clone’s size that determines when 
PNH patients will be symptomatic. However, patients with 
more than 20% of type III RBCs are more likely to develop 
intravascular hemolysis, while patients with large type II and 
absence of significant type III PNH clones may demonstrate 
less hemolysis.14 The PNH clone size of granulocytes and 
monocytes has to be reported also. However, the clone size 
can be highly variable and it is not a good indicator of PNH 
severity by itself. In the International PNH Registry, 1610 
PNH patients were enrolled. The median granulocyte clone 
size was 68% of granulocytes. Small granulocyte clones of 
<10% were detected in 17.4% of patients, clones of 10-49% 
in 15.3% of patients and large clones of >50% of granulocytes 
in 51.7% of patients.24 Patients with clone size 50% or more 
experienced hemoglobinuria, abdominal pain, dysphagia and 
erectile dysfunction as frequently as patients with clone size 
less than 10%.24 In addition, there were patients with large 
PNH clone(s) relatively asymptomatic.9 Nonetheless, it has 
to be emphasized that small PNH clone detection is not 
equivalent to classical PNH diagnosis.14 As it has already been 
mentioned, small PNH clones can be detected in patients with 
AA and RCUD and even very small clones have been observed 
in healthy control subjects.14,19
Patients with established PNH diagnosis have to be moni-
tored annually by flow cytometry, regardless of the PNH clone 
size, as the clone size may increase or decrease over time. 
PNH clone size monitoring more frequently than once a year 
is not required.1,19
In conclusion, flow cytometry is the method of choice 
for PNH clone evaluation regarding patient diagnosis and 
monitoring. Higher sensitivity assays and rare event analysis 
can accurately detect clones in classical PNH but even very 
small PNH clones in subclinical PNH. However, PNH is a 
clinical diagnosis and flow cytometric results should always 
be interpreted with respect to clinical manifestations and 
laboratory findings.
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